Man Group
CKPT

Man Group’s Checkpoint Therapeutics CKPT Stock Holding History

Man Group’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,919
Closed -$34.9K – 2195
2024
Q4 		$34.9K Buy
+10,919
New +$37K ﹤0.01% 1952
2021
Q2 		– Sell
-1,700
Closed -$53K – 1967
2021
Q1 		$53K Buy
+1,700
New +$57K ﹤0.01% 1820

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Man Group's CKPT Position: Q1 2025 in Review

Man Group sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 10,919 shares — an estimated $34.9K sold.

Man Group first reported a position in CKPT in Q1 2021 and held it in 2 quarters. The position peaked at $53K in Q1 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Man Group reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 10,919 Checkpoint Therapeutics shares in Q1 2025, an estimated $34.9K.
  • Man Group first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 2 quarters.
  • Man Group's Checkpoint Therapeutics position peaked at $53K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.